<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-40627" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Drug Enforcement Administration Drug Scheduling</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lopez</surname>
            <given-names>Michael J.</given-names>
          </name>
          <aff>Augusta Un., Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Lopez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-40627.s1" sec-type="Definition/Introduction">
        <title>Definition/Introduction</title>
        <p content-type="pubmed-excerpt">Drug scheduling became mandated under The Federal Comprehensive Drug Abuse Prevention and Control Act of 1970 (also known as the Controlled Substances Act).&#x000a0;The&#x000a0;law addresses controlled substances within Title II.&#x000a0;Based upon this law, the United States Drug Enforcement Agency (DEA) maintains a list of controlled medications and illicit substances categorized from Schedule I to V.<xref ref-type="bibr" rid="article-40627.r1">[1]</xref></p>
        <p>The five categories have their basis on the medication&#x02019;s proper and beneficial medical use and the medication&#x02019;s potential for dependency and misuse or abuse. The purpose of the law is to provide government oversight&#x000a0;over the manufacturing and distribution of these substances. Prescribers and dispensers are required to have a DEA license to supply these drugs. The licensing provides links to users, prescribers, and distributors.<xref ref-type="bibr" rid="article-40627.r2">[2]</xref><xref ref-type="bibr" rid="article-40627.r3">[3]</xref></p>
      </sec>
      <sec id="article-40627.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>The schedules range from Schedule I to V. Schedule I drugs are considered to have the highest risk of abuse, with no recognized medical use in the US, while Schedule V drugs have the lowest potential for abuse. Other factors considered by the DEA include pharmacological effect, evidenced-based knowledge of the drug, the risk to public health, trends in the use of the drug, and whether or not the drug has the potential to be made more dangerous with minor chemical modifications.&#x000a0;</p>
        <p>
<bold>Schedule I:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>"High abuse potential with no accepted medical use; medications within this schedule may not be prescribed, dispensed, or administered"<xref ref-type="bibr" rid="article-40627.r1">[1]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Examples include marijuana (cannabis), heroin, mescaline (peyote), lysergic acid&#x000a0;diethylamide (LSD), methylenedioxymethamphetamine (MDMA), and methaqualone.</p>
          </list-item>
        </list>
        <p>
<bold>Schedule II:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>"High abuse potential with severe psychological or physical dependence; however, these medications have an accepted medical use and may be prescribed, dispensed, or administered"<xref ref-type="bibr" rid="article-40627.r1">[1]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Examples include&#x000a0;fentanyl, oxycodone, morphine, methylphenidate, hydromorphone, amphetamine, methamphetamine ("meth"), pentobarbital,&#x000a0;and secobarbital.</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Schedule II drugs may not receive a refill at the pharmacy</p>
          </list-item>
        </list>
        <p>
<bold>Schedule III:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>"Intermediate abuse potential (ie, less than Schedule II but more than Schedule IV medications)"<xref ref-type="bibr" rid="article-40627.r1">[1]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>&#x000a0;examples include anabolic steroids, testosterone, and ketamine</p>
          </list-item>
        </list>
        <p>
<bold>Schedule IV:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>"Abuse potential less than Schedule II but more than Schedule V medications"<xref ref-type="bibr" rid="article-40627.r1">[1]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Examples include diazepam, alprazolam, and tramadol</p>
          </list-item>
        </list>
        <p>
<bold>Schedule V:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>"Medications with the least potential for abuse among the controlled substances."<xref ref-type="bibr" rid="article-40627.r1">[1]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Examples include pregabalin, diphenoxylate/atropine, dextromethorphan</p>
          </list-item>
        </list>
        <p>Only Drug Enforcement Administration (DEA) registered practitioners can prescribe controlled substances. All prescriptions for Schedule II medications must be&#x000a0;provided to the pharmacist in written form or transmitted by an approved computer system for electronic prescribing of controlled substances (EPCS). Several states now require EPCS systems to be used for controlled substance prescribing. A prescription for a Schedule II medication may be called in by a registered practitioner in an emergency; however, a written prescription must&#x000a0;be provided within 7 days.<xref ref-type="bibr" rid="article-40627.r3">[3]</xref></p>
        <p>Note the following tables for additional information on DEA drug schedules:</p>
        <p><bold>Table 1:&#x000a0;</bold>Information regarding registration, records, prescriptions, refills, distribution, security, and theft or significant loss of controlled substances.</p>
        <p><bold>Table 2: </bold>Information regarding DEA forms 106, 222, 224, and 224a.</p>
      </sec>
      <sec id="article-40627.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Medications are routinely added to the list and can be moved from one category to another as our knowledge and understanding of the medications advance. The DEA maintains a current list on its website under the diversion control division heading. Prescribers may prescribe Schedule II through V medications as allowed by their DEA and state-controlled substance or medical license.</p>
        <p>Not all prescribers are licensed to prescribe all levels of controlled substances as their individual state or DEA licenses limit some,&#x000a0;and&#x000a0;other practitioners are under limitations by their professions, such as advanced practice providers in many states. The prescriber&#x000a0;and the dispensing pharmacist are responsible for knowing&#x000a0;each medication's category and ensuring that only properly licensed individuals prescribe the medications. Healthcare practitioners must understand the DEA controlled-substance scheduling to exercise appropriate caution when prescribing medications with high abuse potential and to ensure against prescribing outside of one's authority.<xref ref-type="bibr" rid="article-40627.r4">[4]</xref><xref ref-type="bibr" rid="article-40627.r5">[5]</xref></p>
        <p>The Controlled Substances Act has&#x000a0;significant potential to improve patient safety by providing federal&#x000a0;oversight&#x000a0;for drugs with&#x000a0;a high potential for misuse and abuse. Prescribers of scheduled substances (physicians, dentists, podiatrists, advanced practitioners) may have links to the distribution of these substances. These practitioners are required to have a DEA license and record prescriptions of scheduled drugs. This licensing prevents overprescribing and obligates providers to&#x000a0;be wary of potential drug-seeking patients.</p>
        <p>The dispenser&#x000a0;must also be aware of&#x000a0;a patient's medication history and be mindful of the potential for polypharmacy if a patient seeks&#x000a0;multiple providers. The current opioid epidemic is a time where&#x000a0;federal oversight and interdisciplinary coordination have the potential to reduce harm to patients prescribed scheduled drugs drastically. However, this change will take additional time and evaluation to determine if drug scheduling reduces misuse, abuse, addiction, and overdose.<xref ref-type="bibr" rid="article-40627.r6">[6]</xref><xref ref-type="bibr" rid="article-40627.r7">[7]</xref><xref ref-type="bibr" rid="article-40627.r8">[8]</xref><xref ref-type="bibr" rid="article-40627.r9">[9]</xref><xref ref-type="bibr" rid="article-40627.r10">[10]</xref></p>
      </sec>
      <sec id="article-40627.s4" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>The healthcare team,&#x000a0;comprised of physicians, advanced practice practitioners, nurses, pharmacists, etc,&#x000a0;must work together to address the proper medical use of controlled substances&#x000a0;for pain control via pharmacotherapy. The healthcare team should schedule their patients for routine follow-up visits, including a history and physical exam, to monitor for adverse drug effects and misuse.</p>
        <p>It is also important to ensure these measures to limit controlled substances do not impair the ability of patients to obtain these medications when there is a legitimate medical need.</p>
        <p>Monitoring for signs of drug misuse is a critical responsibility for the healthcare team because of the epidemic rates of drug misuse worldwide,&#x000a0;particularly in the USA, which leads to death because of respiratory depression as in the case of opioid analgesic overdose (eg, oxycodone, fentanyl). Methods for monitoring drug abuse as well as drug diversion include the following examples: assessment surveys, state prescription drug monitoring programs, urine screening, adherence checklists, motivational counseling, and dosage form counting. [Level 5]</p>
      </sec>
      <sec id="article-40627.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=40627&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=40627">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/40627/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=40627">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-40627.s6">
        <fig id="article-40627.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Controlled Substances Act Summary Table Adapted from Department of Justice website https://www.deadiversion.usdoj.gov/</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CSA__table__summary" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-40627.s7">
        <fig id="article-40627.image.f2" position="float" orientation="portrait">
          <caption>
            <p>DEA forms Adapted from https://www.deadiversion.usdoj.gov/, the website is work of the U.S. Government and is not subject to copyright protection in the United States.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="dea__forms2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-40627.s8">
        <title>References</title>
        <ref id="article-40627.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gabay</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The federal controlled substances act: schedules and pharmacy registration.</article-title>
            <source>Hosp Pharm</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>473</fpage>
            <page-range>473-4</page-range>
            <pub-id pub-id-type="pmid">24421507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40627.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larrat</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Marcoux</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Vogenberg</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>Implications of recent controlled substance policy initiatives.</article-title>
            <source>P T</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-8</page-range>
            <pub-id pub-id-type="pmid">24669180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40627.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gabay</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Federal controlled substances act: controlled substances prescriptions.</article-title>
            <source>Hosp Pharm</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>48</volume>
            <issue>8</issue>
            <fpage>644</fpage>
            <page-range>644-5</page-range>
            <pub-id pub-id-type="pmid">24421533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40627.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Kalava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <chapter-title>Prescription of Controlled Substances: Benefits and Risks</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">30726003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40627.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weyandt</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Oster</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Marraccini</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Gudmundsdottir</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Munro</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Rathkey</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>McCallum</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prescription stimulant medication misuse: Where are we and where do we go from here?</article-title>
            <source>Exp Clin Psychopharmacol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>400</fpage>
            <page-range>400-414</page-range>
            <pub-id pub-id-type="pmid">27690507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40627.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clinton</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Logan</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Lapidus</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Evaluating opioid overdose using the National Violent Death Reporting System, 2016.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>194</volume>
            <fpage>371</fpage>
            <page-range>371-376</page-range>
            <pub-id pub-id-type="pmid">30481691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40627.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rose</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>McBain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>LaRochelle</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Ganz</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Kilambi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Bernson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chui</surname>
                <given-names>KKH</given-names>
              </name>
              <name>
                <surname>Land</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Walley</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Stopka</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Effect of Age on Opioid Prescribing, Overdose, and Mortality in Massachusetts, 2011 to 2015.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>128</fpage>
            <page-range>128-132</page-range>
            <pub-id pub-id-type="pmid">30471102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40627.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lurie</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Throckmorton</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Effect of US Drug Enforcement Administration's Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing.</article-title>
            <source>JAMA Intern Med</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>176</volume>
            <issue>3</issue>
            <fpage>399</fpage>
            <page-range>399-402</page-range>
            <pub-id pub-id-type="pmid">26809459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40627.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <collab>Drug Enforcement Administration, Department of Justice</collab>
            <article-title>Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Final rule.</article-title>
            <source>Fed Regist</source>
            <year>2014</year>
            <month>Aug</month>
            <day>22</day>
            <volume>79</volume>
            <issue>163</issue>
            <fpage>49661</fpage>
            <page-range>49661-82</page-range>
            <pub-id pub-id-type="pmid">25167591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-40627.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Humphreys</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Lembke</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Distribution of Opioids by Different Types of Medicare Prescribers.</article-title>
            <source>JAMA Intern Med</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>176</volume>
            <issue>2</issue>
            <fpage>259</fpage>
            <page-range>259-61</page-range>
            <pub-id pub-id-type="pmid">26658497</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
